Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

作者: P A Bunn , J Crowley , K Kelly , M B Hazuka , K Beasley

DOI: 10.1200/JCO.1995.13.7.1632

关键词:

摘要: PURPOSEThis phase III randomized trial was designed to determine if granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces the hematologic toxicity and morbidity induced by chemoradiotherapy in limited-stage small-cell lung cancer (SCLC).METHODSThis multicenter prospective 230 patients receive chemotherapy radiotherapy (RT) with or without GM-CSF given on days 4 18 of each six cycles. The primary end point toxicity. Secondary points included following: nonhematologic toxicities; (1) fever, (2) antibiotics, (3) hospitalization, (4) infection; number transfusions; drug doses delivered; response rates survival.RESULTSThere a statistically significant increase frequency duration life-threatening thrombocytopenia (P < .001) GM-CSF. had significantly more toxic deaths .01), toxicities, hospital, higher incidence intravenous...

参考文章(47)
A Lindemann, F Herrmann, W Oster, G Haffner, W Meyenburg, LM Souza, R Mertelsmann, Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood. ,vol. 74, pp. 2644- 2651 ,(1989) , 10.1182/BLOOD.V74.8.2644.2644
BR Avalos, JC Gasson, C Hedvat, SG Quan, GC Baldwin, RH Weisbart, RE Williams, DW Golde, JF DiPersio, Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood. ,vol. 75, pp. 851- 857 ,(1990) , 10.1182/BLOOD.V75.4.851.851
GC Baldwin, JC Gasson, SE Kaufman, SG Quan, RE Williams, BR Avalos, AF Gazdar, DW Golde, JF DiPersio, Nonhematopoietic tumor cells express functional GM-CSF receptors Blood. ,vol. 73, pp. 1033- 1037 ,(1989) , 10.1182/BLOOD.V73.4.1033.1033
R Feld, W K Evans, P Coy, I Hodson, A S MacDonald, D Osoba, D Payne, W Shelley, J L Pater, Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. Journal of Clinical Oncology. ,vol. 5, pp. 1401- 1409 ,(1987) , 10.1200/JCO.1987.5.9.1401
J Aisner, M Goutsou, L H Maurer, R Cooper, P Chahinian, R Carey, A Skarin, R Slawson, M C Perry, M R Green, Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. Journal of Clinical Oncology. ,vol. 10, pp. 1230- 1236 ,(1992) , 10.1200/JCO.1992.10.8.1230
D C Ihde, J L Mulshine, B S Kramer, S M Steinberg, R I Linnoila, A F Gazdar, M Edison, R M Phelps, M Lesar, J C Phares, Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. Journal of Clinical Oncology. ,vol. 12, pp. 2022- 2034 ,(1994) , 10.1200/JCO.1994.12.10.2022
K S Albain, J J Crowley, M LeBlanc, R B Livingston, Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. Journal of Clinical Oncology. ,vol. 8, pp. 1563- 1574 ,(1990) , 10.1200/JCO.1990.8.9.1563